You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel QcrB Inhibitors for the Treatment of Tuberculosis

    SBC: LGENIA INC.            Topic: NIAID

    Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Cryopreservation and Cloning of Somatic Cells to Preserve Zebrafish Germplasm

    SBC: FreezeBack, LLC            Topic: OD

    DESCRIPTION provided by applicant Freezing whole zebrafish embryos in order to later recover live fish is not currently possible Researchers seeking to preserve zebrafish genetic lines are presently limited to the options of storing frozen sperm in sperm banks or maintaining the fish alive These limitations increase costs and hinder the efficient dissemination of superior wild type and mutan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Stress forces huESC differentiation; confirmation as an accurate DevTox HTS

    SBC: Reproductive Stress; Measurement, Mechanisms and Management, Corp.            Topic: R

    EXECUTIVE SUMMARY - huESC HTS2 - human Toxic stress effects in 1st trimester pregnancy leads to $10s of billions of US health care costs/year and is a significant part of the $2.5-4B/year US Developmental and Reproductive Technology (DART industry. Current DART techniques use slow, expensive pregnant rodent tests, or tests of embryonic stem cells (ESCs) that are cultured to lose “stemness” and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: PHOTOSONOX LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACT SUMMARY Pyruvate dehydrogenase complex PDC deficiency PDCD is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated Treatment of PDCD remains a serious unmet challenge There has never been a controlled trial of any intervention for PDCD thus there is no proven therapy for affected patients Dichloroacetate DCA ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. General Purpose Radiation Detector Front End and Digital Processor

    SBC: H3D, INC.            Topic: DTRA20B002

    This project aims to create a general-purpose readout architecture that will allow the rapid deployment of next generation detection systems. The system will be based on the development of a programmable general-purpose integrated circuit (GPIC) that has the front-end electronics required to read out signals from a variety of radiation detectors, especially next generation scintillators and semico ...

    STTR Phase I 2021 Department of DefenseDefense Threat Reduction Agency
  9. Fully Metallic Self-Fragmenting Structural Reactive Materials Using Composites and Alloys Comprised of Aluminum, Lithium, and Magnesium

    SBC: Adranos Energetics LLC            Topic: DTRA16A002

    While aluminum casing materials provide some enhanced performance and thermal loading to explosive ordinance, their overall effectiveness is highly limited by incomplete combustion and long residence times. In order to reduce these problems, the casing material must be designed to facilitate rapid fragmentation through either specialized casing geometries or greatly refined initial particle sizes. ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  10. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government